Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook - RNXT News | RalliesOncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
R
RNXT• Drivers of the revenue increase
- Customer expansion — Growth in active commercial cancer center customers and expansion of the commercial pipeline drove revenue gains.
- Repeat utilization — Increased repeat ordering from existing customers contributed to sustained revenue growth.
- Trial site transitions — Transition of Phase III TIGeR-PaC trial sites to commercial use is expected to boost revenue in the second half.
Quarterly loss and analyst view
- Q2 loss per share was $0.06.
- Q2 net loss was $2.91 million.
- Q2 operating expenses were $4.12 million.
- The current average analyst rating on the shares is buy, with 4 strong buy or buy ratings, and no hold, sell, or strong sell ratings.
- Wall Street's median 12-month price target for RenovoRx Inc is $5.50, about 378.3% above its August 11 closing price of $1.15.
Q2 revenue surges and full-year outlook rises
- Targeted oncology device maker's Q2 2026 revenue rose 115% year over year to a record $909,000.
- The company raised full-year 2026 revenue guidance to $3.75 million-$4.25 million from $3.0 million-$4.0 million.
- Active commercial cancer center customers grew to 21, up from 16 in Q1.
- RenovoRx expects Q3 revenue to exceed Q2 and set another record.
- The company anticipates reaching cash-flow break-even in Q4 2027 at a $5 million quarterly revenue run-rate.
